Perrigo Co PLC (PRGO)
35.66
-0.29 (-0.81%)
USD |
NYSE |
Sep 30, 16:00
35.65
-0.01 (-0.03%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.800B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -22.56% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.101 |
| Price to Book Value | 0.9898 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.26 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8489 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 81.59% |
News
Headline
Wire
Time (ET)
MT Newswires
09/12 10:47
PR Newswire
09/12 09:32
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/10/2022* | -- | Results | Q3 2022 | -- | 0.70 | -- | |
| 11/10/2022* | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | 0.43 | 0.44 | -2.60% | |
| 08/09/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/11/2022 | -- | Results | Q1 2022 | 0.33 | 0.42 | -21.56% | |
| 05/11/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 03/01/2022 | -- | Results | Q4 2021 | 0.60 | 0.56 | 6.66% | |
| 03/01/2022 | 08:30 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma. |
| URL | https://www.perrigo.com |
| Investor Relations URL | https://investor.perrigo.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 01, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 1.00 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 1.947 |
| Yield to Sector | 1.550 |
| Yield to Industry | 1.032 |
| Last Dividend Amt. | 0.26 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Sep. 01, 2022 |
| Yield (TTM) | 2.86% |
| Forward Yield | 2.92% |
| Payout Ratio | -114.8% |
| Cash Payout Ratio | 79.73% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 30, 2022.
Fundamentals
| Revenue (TTM) | 4.344B |
| Total Expenses (TTM) | 3.810B |
| Net Income (TTM) | -116.80M |
| Total Assets (Quarterly) | 10.92B |
| Total Liabilities (Quarterly) | 6.070B |
| Shareholders Equity (Quarterly) | 4.850B |
| Cash from Operations (TTM) | 300.60M |
| Cash from Investing (TTM) | -500.10M |
| Cash from Financing (TTM) | 412.80M |
Ratings
Profile
Edit
| Perrigo Co PLC is a leading private label supplier of generic over the counter (OTC) drugs in the U.S. and Europe. The company's product offerings fall under traditional OTC drug categories (i.e. cough, cold, allergy, pain), in addition to oral care, infant nutrition (formula), and nicotine cessation aids. In addition to private label manufacturing, the company also sells products under its own brands (largely in the skincare and oral-care category). The company became a pure-play in OTC consumer healthcare in 2021, following a series of divestitures over several years (sold off generic prescription topicals, animal health, and active pharmaceutical ingredient business). In late 2021, Perrigo signed an offer to acquire HRA Pharma. |
| URL | https://www.perrigo.com |
| Investor Relations URL | https://investor.perrigo.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 01, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| PRGO Tweets |